Six Senses Unveils Women's Wellness Initiative At 5 Luxury Retreats
The setting of Six Senses Douro Valley, one of the five Six Senses retreats currently offering the Female Wellness Program. www.taniasmagicaltravels.com
'As part of the Female Wellness program, fasting is an important element.'
When that was relayed to me as part of the Zoom discussion prior to arriving at Six Senses Douro Valley in Portugal, I wondered whether this was a mistake: I'd been to this property before and knew the food was fantastic. Going there to not eat it didn't make sense, even though I knew that proponents of fasting broadcast its benefits to health. As it was explained, however, their program developed with holistic wellness expert Dr. Mindy Pelz, utilizes individualized fasting schedules as a healing system reset, much like a computer restart. And fortunately for me, my 13 hour fasting requirement was restricted to overnight; all I had to do was adhere to dinner and breakfast times to achieve it.
Yoga at Six Senses Crans-Montana in Switzerland. @John Athimaritis
Six Senses as a company has long been at the forefront of wellness advances in their ever-growing group of international retreats. So it's not a surprise that following a report from the World Economic Forum that there's a notable inequity in healthcare for women due to inadequate data on hormones and health, the company linked with Dr. Pelz to create this program. It was introduced in five Six Senses properties in February—Six Senses Rome, Six Senses Kanuhura in the Maldives, Six Senses Ninh Van Bay in Vietnam, and Six Senses Crans-Montana in Switzerland apart from Douro Valley with others scheduled to add the program this year.
The bedroom of the Panorama Suite in the Quinta. Six Senses
Each guest's program, which can be tailored for three, five or seven days, is structured around her hormonal stage from fertility to perimenopause, menopause and beyond and the aims of the treatment from balancing hormones to increasing vitality and improving sleep. The three-day program explores the foundations of hormonal and metabolic health. The extended five-day program allows for a deeper exploration of the key factors that influence hormonal balance, mood, cravings, sleep, weight, and mental clarity. The seven-day program aims to forge longstanding connections between fasting, food, exercise, self-care, and hormonal balance and places a greater emphasis and intention on weight release, metabolic flexibility, and detox principles that can support long-term hormonal health and overall well-being after the guest returns home.
To assess the starting point, a very thorough biomarker examination happens after check in; the results range from body mass index, strength and exercise recovery capacity to brain serotonin level, heart rate response to challenge and insulin resistance among many others. A glucose monitor is affixed to a guest's arm to monitor fluctuations and at night, guests wear a sleep ring to analyze what's going on then. It's remarkably detailed; even if you think you sleep pretty well, what you discover can be really surprising. Facets of the Three Day Program
Tibetan Singing Bowl Meditation. Six Senses
Depending upon what a guest's health assessment dictates, a three day program can contain personal training, a sleep consultation, sound meditation with Tibetan bowls, guided meditation, a biohacking session with leg compression and red light therapy and given the company's excellent traditional spa services, a de-stressing holistic massage. Personal time is also included for lazing by the indoor or outdoor swimming pools and taking part in scheduled group activities such as kayaking, local touring on E-bikes, yoga and, since this is a famous wine area, wine tasting-the property has a serious wine tasting program. The Culinary Program
The open kitchen of the restaurant Vale de Abraão surrounded by some of the organic vegetables used in dishes on the menu. John Athimaritis
The menus designed for each Female Wellness guest are crafted specifically to their needs but are in line with the company's overall sustainable, local, healthful plans. And as I remembered, the food here with many ingredients grown in their organic gardens was so vibrant that I cheated extensively and ordered off the regular menu, including grabbing a section of vegetable salads off the breakfast buffet that were so colorful and lively that even those who don't love vegetables would love these. (As one staff member said to me when I admitted my cheating, they're not wardens so they don't force guests to submit. He also admitted that he thought the Rome property might be the hardest one in which to stick to the rules and the Crans-Montana resort the easiest.)
Organic Heirloom Seasonal Tomatoes with strawberries, tomato water, aguachile and aged Bageiras red wine vinegar at the restaurant Vale de Abraão at Six Senses Douro Valley. Laurie Werner
Dishes such as Organic Heirloom Seasonal Tomatoes with strawberries, tomato water, aguachile and aged Bágeiras red wine vinegar, Atlantic Grilled Fish with Salsa Verde and because it was white asparagus season, Roasted White Asparagus with House Miso and Cured Egg Yolk were so good, I had each twice. But the menu that was designed for me was hardly one of deprivation and often, in fact, very similar with dishes such as Atlantic Whole Line Caught Fish with Smoky Bean and Hazelnut Salad; Peach and Almond Crumble and Grilled Sirloin Steak with peas, red onion, basil and walnut salad. One of the restaurants, Cozinha do Douro, spotlights local specialties but the main restaurant Vale de Abraão with its open kitchen, wood fired specialties, chef creations and balcony overlooking terraced vineyards was the one I gravitated to the most.
Apart from everything I learned about rebalancing, de-stressing and hopefully better sleeping, it was also the aspect I wanted most to repeat. I'm not sure I can replicate what the chef did but I asked for the recipes. MORE FROM FORBES Forbes Tuning Up For The New Year At Transformative SHA Wellness Mexico By Laurie Werner Forbes The British Virgin Islands Resort Oil Nut Bay Adds New Villas And Spa By Laurie Werner Forbes Kaua'i's Serene 1 Hotel Hanalei Bay Debuts A Sweeping Wellness Plan By Laurie Werner Forbes Sensei Porcupine Creek, A Unique Wellness Retreat, Opens On Larry Ellison's Estate By Laurie Werner
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
28 minutes ago
- Medscape
Novel Drug Lowers Urate Levels but Gout Flares Persist
BARCELONA, Spain — The investigational oral compound SAP-001 had a significant and sustained urate-lowering effect in people with refractory gout, according to findings of a phase 2b study reported at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. The proportion of people achieving a target serum urate level of < 6 mg/dL (360 µ mol/L) after 12 weeks was 10.5% for placebo and ranged from 43.8% to 70.0% for those given one of three different once-daily doses of SAP-001. A dose response was not seen in the main analysis, however; the proportions of people meeting this primary efficacy endpoint were 43.8% (n = 32) for a 60-mg dose but 56.3% (n = 16) and 70.0% (n = 20) for 10- and 30-mg doses, respectively. Kenneth Saag, MD This could have been because of issues with adherence, said the presenting author Kenneth Saag, MD, professor and director of the Division of Clinical Immunology and Rheumatology at The University of Alabama at Birmingham. Ad hoc analyses, which had not been preplanned, showed that 'some subjects had not been exposed to the drug post baseline,' Saag said. 'This seemed to strongly correlate with adherence to therapy, as indicated by [a patient's daily] dosing diary, pill counts, and post-study patient interviews.' When people with nonquantifiable serum urate levels were excluded from the analyses, there was more of a dose response, particularly if a lower urate level of < 5 mg/dL (300 µ mol/L) had been achieved. Notably, Saag reported that the urate-lowering effects were maintained until the end of treatment at 6 months, and a good proportion of participants also met the harder target of a serum urate level of < 5 mg/dL. First-in-Class 'SAP-001 is a drug that has a different renal urate transporter mechanism of action from other urate-lowering drugs that are currently available or are under development,' said Saag, a former president of the American College of Rheumatology. Although Saag did not present the specific mode of action for the drug, he noted, 'it appears to predominantly be targeting GLUT [glucose transporter] 9, which is located on the basal lateral aspect of the renal tubule.' This differs from most other uricosuric therapies, which targeted renal transporters on 'the apical side of the tubule, such as OAT [organic anion transporters] and URAT [urate transporter]-1,' he added. 'So this drug has the potential as a novel therapeutic option in gout,' Saag said. Study Design and Patient Population The study was a 6-month randomized, double-blinded, placebo-controlled investigation of three different doses of SAP-001 for the management of refractory gout. A total of 403 adults with refractory gout between 18 years and 75 years of age who were living in the US were screened for eligibility, with 87 finally randomized. For inclusion, participants had to either have not responded to at least 4 weeks of standard of care treatment with a xanthine oxidase inhibitor prior to study entry or have a contraindication to its use. They also had to have serum urate levels of ≥ 7 mg/dL at both the screening and randomization visit. A 1:1:1:2 ratio was used to randomly allocate participants to the four treatment groups: placebo or SAP-001 10 mg, 30 mg, or 60 mg. Baseline characteristics were reasonably similar among the four groups. The mean ages in each group were 55.9 years, 54.2 years, 50.3 years, and 52.5 years, respectively. The majority were men (89.5%, 87.5%, 90.0%, and 96.9%, respectively), and most identified themselves as White and Hispanic individuals. The mean BMI was around 32, and baseline serum urate levels were about 8.37 mg/dL (~500 µ mol/L). The average duration of gout since diagnosis was about 10 years, and 1 in 5 had palpable tophi. Safety Findings Saag and associates reported in their abstract that SAP-001 was well tolerated overall. There were no treatment-emergent serious adverse events in the SAP-001 patients, and all adverse events were of a mild to moderate intensity. The most frequently reported adverse events were gout flares; these occurred in 26.3% of placebo-treated individuals and in 25%, 30%, and 25% of participants treated with SAP-001 10 mg, 30 mg, and 60 mg, respectively. The majority of these gout flares occurred within the first few months of the study, although some people taking SAP-001 experienced gout flares up to 4-6 months later. The longest duration of gout flares in the SAP-001 groups was 11.5 days in the 60-mg SAP-001 group, and the shortest was 6.2 days in the 30-mg group. The mean durations of gout flares in the 10-mg and placebo groups were 6.5 and 7.4 days, respectively. The time to the first gout flare was shortest in the 30-mg SAP-001 group, at 21.2 days, followed by 40.5 days in the 60-mg group, 50.3 days in the 10-mg group, and 66.4 days in the placebo group. As for adverse events of special interest, one participant who had taken the 30-mg dose of SAP-001 developed a hepatobiliary disorder, and another who had taken this dose had raised aspartate aminotransferase, an outcome that also occurred in one patient each in the 10- and 60-mg dosing groups. Increased blood creatinine levels were seen in two participants in the 10-mg group and three in the 60-mg group. Hepatic enzymes were elevated in one patient in the placebo group and one patient in the 30-mg group. One patient in the 60-mg group had acute kidney injury. Limitations and Conclusion Saag acknowledged that this was an early-phase study, and its small sample size meant the effect on flares and tophi was limited. However, he concluded that SAP-001 may be a 'novel, efficacious, and generally safe oral urate-lowering treatment option for difficult-to-treat gout populations, and it merits further investigation with a focus on treatment adherence.' Helga Lechner-Radner, Wien, Austria, who co-chaired the late-breaking abstract session during which Saag had presented these data, questioned whether people with genetic conditions that could cause hyperuricemia had been included or excluded from the study. Saag responded: 'That wasn't specifically a form of [inclusion]/exclusion in this study; in future studies, that would certainly be reasonable to look at.' This study was funded by Shanton Pharma. Saag reported acting as a consultant to Shanton Pharma as well as Amgen, Arthrosi, ATOM, Crystalys, LG, and Sobi. He also reported being an investigator for Arthrosi, Crystalys, Inventis, and LG. Several coauthors on the abstract were employees of Shanton Pharma.
Yahoo
an hour ago
- Yahoo
Dutch consumer groups prepare legal action against Booking.com, alleging inflated hotel prices
AMSTERDAM (Reuters) -Two Dutch consumer groups said on Wednesday they are seeking affected customers for a legal claim against one of the world's largest online travel agencies, over what they described as inflated hotel prices since 2013. The Consumer Competition Claims Foundation (CCC) and the Consumers' Association said in a statement that had allegedly been charging consumers too much for hotel rooms for years, leading to "hundreds of millions of euros in damage to Dutch consumers". "We have done research and it shows that Booking has been violating competition rules and consumer law since January 2013," CCC Chairman Bert Heikens said. did not respond immediately to a request for comment. In 2024, the EU's top court ruled that restrictions against hotels offering lower rates on their websites or on rival sites were unnecessary and could reduce competition, but also that such clauses were not anti-competitive under EU laws. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
Upstream phase of LUMEVOQ® manufacturing process successfully transferred Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and dose-ranging study in France Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions PARIS, June 26, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company's gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent, Inc. "This outstanding result is a significant milestone in GenSight's strategy for securing the supply of LUMEVOQ for clinical use and for supporting the planned regulatory submissions," commented Scott Jeffers, Chief Technical Officer of GenSight Biologics. "Our new partnership is proving to be highly effective, not just in completing the tech transfer process successfully, but also in improving the yield and upgrading the analytical methods used to reinforce control over the safety and quality of each batch. The level of collaboration and coordination between our teams has been truly impressive." Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. It is the only CDMO with a successfully commercialized gene therapy produced in their facility. Catalent offers gene therapy companies both production and in-house testing capabilities, and the GMP capacity at the facility used for LUMEVOQ® will provide GenSight Biologics greater flexibility in the manufacture of the gene therapy. Catalent successfully manufactured the drug product batch that was released as safe for human use in November 2024 and which will be the source of product supply for the named patient early access program (AAC) and dose-ranging study in France. After the tech transfer is completed, Catalent will also manufacture the drug for the planned global Phase III trial RECOVER and the regulatory submissions. The Partnership as a Critical Element of GenSight Biologics' Strategy Following agreement with the French agency ANSM to consider opening the AAC program expeditiously after approval of a dose-ranging study, the Company is currently implementing a financing strategy, as it continues to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner (Catalent) to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom "Our partnership with a manufacturing powerhouse like Catalent is a critical enabler of our global strategy," explained Laurence Rodriguez, CEO of GenSight Biologics. "The outputs from their work with our team will allow us to reassure regulators that we have surmounted the challenges we faced in the past and, ultimately, to fulfill our mission to provide LHON patients a safe and effective treatment for their urgent unmet need." About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. About Leber Hereditary Optic Neuropathy (LHON) Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of subjects have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. About LUMEVOQ® (GS010; lenadogene nolparvovec) LUMEVOQ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. "LUMEVOQ" was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ® (GS010; lenadogene nolparvovec) has not been registered in any country at this stage. View source version on Contacts GenSight Biologics Chief Financial OfficerJan Eryk Umiastowskijeumiastowski@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
